Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Robert F. Werner has filed a notice of proposed sale of 7,000 common shares, with an aggregate market value of $319,532.51, to be sold through Fidelity Brokerage Services LLC on NASDAQ around 02/04/2026. The filing lists 61,311,704 common shares outstanding.
The 7,000 shares come from restricted stock that vested as compensation between 05/22/2024 and 02/02/2025, in multiple smaller tranches. The notice also reports past three-month sales by Werner totaling 1,456 shares across four transactions, with disclosed gross proceeds for each sale.
Patrick Finn has filed notice to sell 2,705 shares of common stock of TWST on or about 02/03/2026 through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $125,986.73.
The shares to be sold were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Finn reported several sales of TWST common stock, including 23,279 shares on 01/13/2026 for $931,160.00 and 2,390 shares on 01/23/2026 for $107,329.41.
A shareholder of TWST has filed a Rule 144 notice to sell 175 shares of common stock on the NASDAQ through Fidelity Brokerage Services, with an approximate sale date of February 3, 2026.
The 175 shares were acquired on February 2, 2026 through restricted stock vesting from the issuer as compensation. The filing also lists recent sales for the same seller, including 160 common shares sold on November 3, 2025 for $5,132.70 and 822 common shares sold on November 24, 2025 for $23,599.21. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
TWST shareholder Paula Green filed a Rule 144 notice to sell 1,194 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $55,611.15, when 61,311,704 shares were outstanding and the approximate sale date listed as 02/03/2026.
The shares to be sold were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Green reported four separate common stock sales between 11/03/2025 and 12/22/2025. By signing, she represents she is not aware of undisclosed material adverse information about the issuer.
Twist Bioscience insider plans to sell common stock under Rule 144. Dennis H. Cho filed a notice to sell 1,099 common shares through Fidelity Brokerage Services on NASDAQ around 02/03/2026, with an aggregate market value of $51,186.47. The issuer has 61,311,704 common shares outstanding.
The 1,099 shares to be sold were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, Cho has sold additional common shares: 1,019 shares for $32,688.91 on 11/03/2025, 757 shares for $20,063.15 on 11/21/2025, 398 shares for $13,085.28 on 12/08/2025, and 324 shares for $11,196.14 on 12/22/2025.
An insider of the company trading under symbol TWST has filed a Rule 144 notice to sell 5,001 shares of common stock through Fidelity Brokerage Services LLC on or about 02/03/2026 on the NASDAQ, with an aggregate market value listed as $232,924.08.
The 5,001 shares were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. The filer also reports prior sales in the last three months, including 4,887 common shares sold on 11/03/2025 for gross proceeds of $156,772.03. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
Twist Bioscience Corporation disclosed that investment manager Artisan Partners and related entities filed an amended Schedule 13G reporting a sizable passive stake. The group reports beneficial ownership of 5,830,205 shares of Twist common stock, or 9.5% of the class, based on 61,273,653 shares outstanding as of 12/26/2025.
Artisan entities report no sole voting or dispositive power. They share voting power over 4,959,392 shares and share dispositive power over 5,830,205 shares, held on behalf of discretionary clients of Artisan Partners Limited Partnership. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Twist Bioscience.
Twist Bioscience Corp reported a significant shareholder update as of December 31, 2025. ARK Investment Management LLC and its founder Catherine D. Wood together beneficially own 7,559,495 shares of Twist common stock, representing 12.36% of the outstanding class.
ARK holds sole voting power over 7,091,113 shares and sole dispositive power over all 7,559,495 shares. Catherine Wood has shared voting power over 7,227,245 shares and shared dispositive power over 7,559,495 shares, reflecting her control role at ARK.
The filing states that these securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Twist Bioscience, and not in connection with any control-related transaction. ARK also notes that its client ARK Innovation ETF has an interest in more than 5% of the reported securities.
Twist Bioscience reported quarterly revenue of $103.7 million for the three months ended December 31, 2025, up 16.9% from $88.7 million a year earlier. Growth came from both DNA synthesis and protein solutions and NGS applications, with particularly strong demand from therapeutics and global supply partners.
Gross margin improved to 52.0% from 48.3% as higher volume and process improvements offset cost increases. The company still recorded a net loss of $30.5 million, slightly better than the $31.6 million loss last year, and used $24.8 million in operating cash.
Cash, cash equivalents and short-term investments totaled $197.9 million, and management believes this balance is sufficient to fund operations for at least one year. Operating expenses shifted, with lower research and development spending and higher selling, general and administrative costs to support commercial scaling.
Twist Bioscience Corporation filed a current report to note that it issued a press release announcing its financial results for the quarter ended December 31, 2025. The press release, titled “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results”, is furnished as Exhibit 99.1.
The company states that the information in this report, including Exhibit 99.1, is being furnished rather than filed under the Securities Exchange Act of 1934 and is not automatically incorporated by reference into Securities Act registration statements unless specifically referenced.